HACKENSACK, N.J., May 3, 2018 /PRNewswire/ -- Champions Oncology,
Inc. (Nasdaq: CSBR), engaged in the development of advanced
technology solutions and services to personalize the development
and use of oncology drugs, today announced that management will be
presenting at the 3rd annual Disruptive Growth & Healthcare
Conference on Wednesday, May 9th at
8:40am. The conference is being
hosted by RHK Capital and ReedSmith LLP, at Reed Smith's offices
located at 599 Lexington Avenue.
The 2018 Disruptive Growth & Healthcare Conference will
offer the exclusive opportunity to discover life science companies
focusing on solutions to unmet medical needs and growth companies
with disruptive technologies and business models.
About RHK Capital
Advisory Group Equity Services, Ltd. (dba RHK Capital) was
founded in 1984. RHK Capital is a boutique investment banking firm
specializing in small to medium-sized transactions. RHK is led by a
management team with extensive financial industry experience and a
desire to provide companies and individuals with the tools and
expertise to accomplish their financial goals. In addition to
investment banking, RHK has grown to include businesses in general
securities, emerging market securities, distressed and high yield
debt securities, investment management, mortgages, and business
lending. As a division of Advisory Group Equity Services (AGES),
all securities are offered through Advisory Group Equity Services
Ltd., a registered broker-dealer, member of the Financial Industry
Regulatory Authority and the Securities Investor Protection
Corporation.
For those interested in attending, please visit
www.DisruptNYC.com for more information.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's TumorGraft
technology platform is a novel approach to personalizing cancer
care based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company uses
this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business. For more information, please
visit www.championsoncology.com.
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-to-present-at-the-3rd-annual-disruptive-growth--healthcare-conference-on-may-9th-300641528.html
SOURCE Champions Oncology, Inc.